Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals, a research-driven, integrated pharmaceutical company, has begun Phase II study for GBR 500, an antagonist of the VLA2 (alpha2-beta1) integrin, for Ulcerative Colitis (UC).
Subscribe to our email newsletter
The randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of GBR 500 in patients with moderate to severe UC.
Glenmark Pharmaceuticals chief scientific officer Dr. Michael Buschle said despite treatment advances in recent years, UC remains a debilitating condition for many individuals, and represents an area of substantial unmet medical need.
"We’re pleased with the continued progress of our partnership with Sanofi and excited about the commencement of this trial," Dr. Buschle added.
The placebo-controlled study will be conducted at multiple clinical sites in North America and Europe and includes approximately 84 patients.
Patients participating in the study will receive multiple doses of either GBR 500 or placebo, administered over a period of several weeks.
The trial is part of a strategic global collaboration between Glenmark and Sanofi to investigate GBR 500 for the treatment of chronic inflammatory disorders.